High-priced specialty drugs spur calls for competition

April 15, 2015 2:14 PM

4 0

High-priced specialty drugs spur calls for competition

"Prices are way too high, much higher than they need to be," said Peter Bach, director of Memorial Sloan Kettering's Center of Health Policy and Outcomes.

"Prices are so high that [pharmaceutical companies] are coming like a wave of contractors after a hurricane into the space because they're being paid premium prices to rush there."

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...